These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3803424)

  • 21. Fansidar for malaria prophylaxis.
    Kissane D
    Aust Fam Physician; 1985 Aug; 14(8):738. PubMed ID: 3901990
    [No Abstract]   [Full Text] [Related]  

  • 22. Possible sulfadoxine-pyrimethamine resistance in Plasmodium falciparum malaria from Kenya.
    Markwalder KA; Meyer HE
    Trans R Soc Trop Med Hyg; 1982; 76(2):281. PubMed ID: 7048656
    [No Abstract]   [Full Text] [Related]  

  • 23. [Mefloquine and sulfadoxine/pyrimethamine overdose in malaria tropica].
    Burgmann H; Winkler S; Uhl F; Feucht M; Hellgren U; Bergqvist Y; Feistauer S; Breyer S; Graninger W
    Wien Klin Wochenschr; 1993; 105(2):61-3. PubMed ID: 8442357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria.
    Akinyotu O; Bello F; Abdus-Salam R; Arowojolu A
    Int J Gynaecol Obstet; 2018 Aug; 142(2):194-200. PubMed ID: 29719927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malaria in travelers returning from Kenya: failure of self-treatment with pyrimethamine/sulfadoxine.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1989 May; 38(20):363-4. PubMed ID: 2497333
    [No Abstract]   [Full Text] [Related]  

  • 26. Tolerability of long-term malaria prophylaxis with the combination mefloquine + sulfadoxine + pyrimethamine (Fansimef): results of a double blind field trial versus chloroquine in Nigeria.
    Kollaritsch H; Stemberger H; Mailer H; Kremsner P; Kollaritsch R; Leimer R; Wiedermann G
    Trans R Soc Trop Med Hyg; 1988; 82(4):524-9. PubMed ID: 2908258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Falciparum malaria despite pyrimethamine/suifadoxine in five tourists to East Africa.
    Eichenlaub D; Rogler G; Hoffmann HG; Weise HJ
    Lancet; 1982 Nov; 2(8306):1041-2. PubMed ID: 6127518
    [No Abstract]   [Full Text] [Related]  

  • 28. [Eosinophilic lung infiltration during malaria prophylaxis with pyrimethamine-sulfadoxine (Fansidar)].
    Buser P; Räber J
    Schweiz Med Wochenschr; 1985 Aug; 115(34):1174-6. PubMed ID: 4048913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Falciparum malaria resistant to chloroquine and fansidar: implications for prophylaxis.
    Herzog C; Kibbler CC; Ellis CJ; Mtawali CV
    Br Med J (Clin Res Ed); 1983 Oct; 287(6397):947-8. PubMed ID: 6412900
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse reactions to Fansidar and updated recommendations for its use in the prevention of malaria.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1985 Jan; 33(51-52):713-4. PubMed ID: 3917533
    [No Abstract]   [Full Text] [Related]  

  • 31. Indications for the use of Fansidar in malaria.
    Schwartz IK; Campbell CC
    N Engl J Med; 1982 Jul; 307(3):194. PubMed ID: 7088068
    [No Abstract]   [Full Text] [Related]  

  • 32. The first report of Plasmodium falciparum resistant to chloroquine plus sulphadoxine/pyrimethamine in Rwanda.
    Giboda M; Vanista J; Dastych P
    Trans R Soc Trop Med Hyg; 1988; 82(3):383. PubMed ID: 3068850
    [No Abstract]   [Full Text] [Related]  

  • 33. Need for malaria prophylaxis by travelers to areas with chloroquine-resistant Plasmodium falciparum.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 Jan; 35(2):21-22, 27. PubMed ID: 3001495
    [No Abstract]   [Full Text] [Related]  

  • 34. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis.
    Miller KD; Lobel HO; Satriale RF; Kuritsky JN; Stern R; Campbell CC
    Am J Trop Med Hyg; 1986 May; 35(3):451-8. PubMed ID: 2939735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo and in vitro susceptibility of Plasmodium falciparum to sulphadoxine/pyrimethamine in Liberia, West Africa.
    Björkman A; Willcox M
    Trans R Soc Trop Med Hyg; 1986; 80(4):572-4. PubMed ID: 3544359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leads from the MMWR. Need for malaria prophylaxis by travelers to areas with chloroquine-resistant Plasmodium falciparum.
    JAMA; 1986 Feb; 255(5):597. PubMed ID: 3003409
    [No Abstract]   [Full Text] [Related]  

  • 37. In vivo assessment of the sensitivity of Plasmodium falciparum to sulphadoxine/pyrimethamine combination (Fansidar) in six localities in Tanzania where chloroquine-resistant P. falciparum has been detected.
    Kilimali VA; Mkufya AR
    Trans R Soc Trop Med Hyg; 1985; 79(4):482-3. PubMed ID: 3909553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sulfadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria.
    Botero D; Restrepo M; Montoya A
    Bull World Health Organ; 1985; 63(4):731-7. PubMed ID: 3910296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of malaria with sulfadoxine/pyrimethamine: note of caution.
    Gozal D; Hengy C
    Lancet; 1990 Jul; 336(8707):111-2. PubMed ID: 1975290
    [No Abstract]   [Full Text] [Related]  

  • 40. Low serum folate among persons taking Fansidar (pyrimethamine plus sulfadoxine) for prophylaxis of malaria.
    Stürchler D; Holzer B
    Acta Trop; 1980 Sep; 37(3):243-8. PubMed ID: 6106361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.